Compare Moderna, Inc. (MRNA) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Uber Technologies Inc — how do they compare? Moderna, Inc. trades at $196.55 (market cap $78.65B), while Uber Technologies Inc trades at $70.18 (market cap $143.47B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Uber Technologies Inc for 88 Days on average.
| MRNA | UBER | |
|---|---|---|
Market Cap | $78.65B | $143.47B |
Volume | 37,373,437 | 14,430,657 |
Sector | Health | Technology |
52-Week High | $203.46 | $99.72 |
52-Week Low | $22.36 | $65.94 |
Typical Hold Time | 59 Days | 88 Days |
Enterprise Value | $74.80B | $152.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Uber trades at $68.45, down 0.91% on the day, with a bearish technical signal despite strong fundamentals. The company reported $52.02B revenue in 2025 with $10.05B net income, maintaining robust growth from $44.0B revenue in 2024. Recent expansion includes the Costco delivery partnership reaching 47 states, while CEO Dara Khosrowshahi purchased $10 million in shares, signaling confidence.
Uber presents a compelling growth story with expanding profitability and dominant market position, though technical indicators suggest near-term pressure. The consensus price target of $104.72 implies 53% upside, supported by 82.5% analyst buy ratings. Key risks include robotaxi competition and projected negative cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
